Expanding surgical treatment of pancreatic cancer: The role of regional chemotherapy

Pancreas

Volumn 41, Issue 5, 2012, Pages 678-684

  Davis, Jeremy L ^a   Pandalai, Prakash K ^a   Ripley, R Taylor ^a   Langan, Russell C ^a   Avital, Itzhak ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chemotherapy; Infusion; Intra arterial; Pancreatic cancer; Regional perfusion

Indexed keywords

ANGIOTENSIN II; CARBOPLATIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; GASTROINTESTINAL TOXICITY; HUMAN; MIXED TUMOR; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PRIMARY TUMOR; PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84863651135     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318249955a     Document Type: Review

References (49)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
3. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama. 2007;297:267-277.
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
5. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-3785.
6. Yip D, Karapetis C, Strickland A, et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006;3:CD002093.
7. Key C. Cancer of the pancreas. SEER survival monograph: cancer survival among adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. In: Ries LAG YJ, Keel GE, Eisner MP, et al, eds. Edition National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD. 2007.
8. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. New York: Springer; 2010.
9. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727-1733.
10. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035-1046.
11. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984;2:498-504.
12. Creech O Jr, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-632.
13. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24:4196-4201.
14. Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol. 1999;6:582-590.
15. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007.
16. Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011-4019.
17. Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635-644.
18. Fiorentini G, Poddie D, Ricci S, et al. Intra-aortic stop-flow infusion (IASFI) with hypoxic abdominal perfusion (HAP) in UICC stage III/IV pancreatic carcinoma (PC): report of a phase II study. Regional Cancer Treatment. 1996;9:88-91.
19. Muchmore JH, Preslan JE, George WJ. Regional chemotherapy for inoperable pancreatic carcinoma. Cancer. 1996;78:664-673.
20. Link KH, Gansauge F, Gorich J, et al. Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur J Surg Oncol. 1997;23:409-414.
21. Lorenz M, Petrowsky H, Heinrich S, et al. Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer. Eur J Surg Oncol. 1998;24:542-547.
22. Maurer CA, Borner MM, Lauffer J, et al. Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer. Int J Pancreatol. 1998;23:181-186.
23. Klapdor R, Seutter E, Lang-Polckow EM, et al. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers. Anticancer Res. 1999;19:2459-2469.
24. Homma H, Doi T, Mezawa S, et al. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer. 2000;89:303-313.
25. Bayar S, Unal E, Tez M, et al. Regional chemotherapy for advanced pancreatic carcinoma. Hepato-gastroenterology. 2003;50:550-552.
26. Ohigashi H, Ishikawa O, Yokayama S, et al. Intra-arterial infusion chemotherapy with angiotensin-II for locally advanced and nonresectable pancreatic adenocarcinoma: further evaluation and prognostic implications. Ann Surg Oncol. 2003;10:927-934.
27. van Ijken MG, van Etten B, Guetens G, et al. Balloon catheter hypoxic abdominal perfusion with mitomycin C and melphalan for locally advanced pancreatic cancer: a phase IYII trial. Eur J Surg Oncol. 2004;30:671-680.
28. Aigner KR, Gailhofer S. Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer-a phase II study on 265 cases. Anticancer Res. 2005;25:4407-4412.
29. Takamori H, Kanemitsu K, Tsuji T, et al. 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer. Pancreas. 2005;30:223-226.
30. Barletta E, Fiore F, Daniele B, et al. Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma. Front Biosci. 2006;11:782-787.
31. Mambrini A, Sanguinetti F, Pacetti P, et al. Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience. In Vivo. 2006;20:751-755.
32. Meyer F, Gebauer T, Grote R, et al. Results of regional chemotherapy using the aortic stop-flow technique in advanced pancreatic carcinoma. Surg Today. 2006;36:155-161.
33. Guadagni S, Clementi M, Valenti M, et al. Hypoxic abdominal stop-flow perfusion in the treatment of advanced pancreatic cancer: a phase II evaluation/trial. Eur J Surg Oncol. 2007;33:72-78.
34. Ikeda O, Tamura Y, Nakasone Y, et al. Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma. Cardiovasc Intervent Radiol. 2007;30:912-921.
35. Ishikawa T, Kamimura H, Tsuchiya A, et al. Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer. Hepato-gastroenterology. 2007;54:2378-2382.
36. Milandri C, Calzolari F, Passardi A, et al. Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience. Hepato- gastroenterology. 2007;54:2373-2377.
37. Nakchbandi W, Muller H, Singer MV, et al. Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. J Gastrointestin Liver Dis. 2008;17:285-290.
38. Sasada T, Denno R, Tanaka T, et al. Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study. Am J Clin Oncol. 2008;31:71-78.
39. Mambrini A, Bassi C, Pacetti P, et al. Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy. Pancreas. 2008;36:56-60.
40. Saif MW. Pancreatic neoplasm in 2011: an update. JOP. 2011;12:316-321.
41. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
42. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
43. Crane CH, Winter K, Regine WF, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol. 2009;27:4096-4102.
44. Willett CG, Czito BG, Bendell JC, et al. Locally advanced pancreatic cancer. J Clin Oncol. 2005;23:4538-4544.
45. Loyer EM, David CL, Dubrow RA, et al. Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging. 1996;21:202-206.
46. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168:1439-1443.
47. Morganti AG, Massaccesi M, La Torre G, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010;17:194-205.
48. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836-847.
49. Yekebas EF, Bogoevski D, Cataldegirmen G, et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg. 2008;247:300-309.